Joshua Savage

Citée par

	Toutes	Depuis 2019
Citations	675	513
indice h	11	10
indice i10	11	10

140

105

20132014201520162017201820192020202120222023202410 13 22 28 32 48 51 73 128 98 111 49

Accès public

Tout afficher

16 articles

1 article

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Lucinda BillinghamUniversity of BirminghamAdresse e-mail validée de bham.ac.uk
Yvonne SummersThe Christie Hospital NHS Trust, Manchester University NHS TrustAdresse e-mail validée de christie.nhs.uk
Sanjay POPATRoyal Marsden HospitalAdresse e-mail validée de rmh.nhs.uk
Kristian BrockAstraZenecaAdresse e-mail validée de astrazeneca.com
Robert GoggsCornell UniversityAdresse e-mail validée de cornell.edu
Prof. Siow Ming LeeProfessor of Medical Oncology, UCL/UCLH, LondonAdresse e-mail validée de nhs.net
Christina YapThe Institute of Cancer ResearchAdresse e-mail validée de icr.ac.uk
Hisham MehannaDirector and Professor, Institute of head and Neck Studies and Education, Uni of BirminghamAdresse e-mail validée de bham.ac.uk
Joseph J SaccoReader, Department of Molecular and Clinical Cancer Medicine, University of LiverpoolAdresse e-mail validée de liverpool.ac.uk
colin WattsProfessor of Neurosurgery University of BirminghamAdresse e-mail validée de bham.ac.uk
Jo ParishUniversity of BirminghamAdresse e-mail validée de bham.ac.uk
Amanda KirkhamSenior Biostatistician, Cancer Research Clinical Trials Unit, University of Birmingham, UKAdresse e-mail validée de bham.ac.uk
Victoria WykesSenior Clinical Lecturer, Honorary Consultant Neurosurgeon: University of BirminghamAdresse e-mail validée de bham.ac.uk
John R AppsAdresse e-mail validée de doctors.net.uk
David GilliganConsultant Oncologist Cambridge Univerisity Hospitals, Cambridge, UKAdresse e-mail validée de nhs.net
alastair greystokeNewcastle UniversityAdresse e-mail validée de newcastle.ac.uk
Piers GauntPrincipal BiostatisticianAdresse e-mail validée de bham.ac.uk
Neil StevenUniversity of BirminghamAdresse e-mail validée de bham.ac.uk
Gareth VealProfessor of Cancer Pharmacology, Newcastle UniversityAdresse e-mail validée de ncl.ac.uk
Julie IrvingNewcastle UniversityAdresse e-mail validée de ncl.ac.uk

Suivre

Joshua Savage

Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham

Adresse e-mail validée de bham.ac.uk - Page d'accueil

cancer clinical trials NSCLC lung precision medicine


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial G Middleton, K Brock, J Savage, R Mant, Y Summers, J Connibear, ... The Lancet Respiratory Medicine 8 (9), 895-904, 2020	144	2020
The National Lung Matrix Trial of personalized therapy in lung cancer G Middleton, P Fletcher, S Popat, J Savage, Y Summers, A Greystoke, ... Nature 583 (7818), 807-812, 2020	130	2020
Dysfunction of the PI3 kinase/Rap1/integrin αIIbβ3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia SF Moore, RW Hunter, MT Harper, JS Savage, S Siddiq, SK Westbury, ... Blood 121 (7), 1209-1219, 2013	58	2013
Syntaxin 8 regulates platelet dense granule secretion, aggregation, and thrombus stability EM Golebiewska, MT Harper, CM Williams, JS Savage, R Goggs, ... Journal of Biological Chemistry 290 (3), 1536-1545, 2015	53	2015
Munc13‐4 is critical for thrombosis through regulating release of ADP from platelets JS Savage, CM Williams, O Konopatskaya, I Hers, MT Harper, AW Poole Journal of Thrombosis and Haemostasis 11 (4), 771-775, 2013	44	2013
Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial G Middleton, K Brock, YJ Summers, J Connibear, R Shah, C Ottensmeier, ...	40	2018
The small GTPase Rif is dispensable for platelet filopodia generation in mice R Goggs, JS Savage, H Mellor, AW Poole PLoS ONE 8 (1), e54663, 2013	39	2013
RhoG protein regulates platelet granule secretion and thrombus formation in mice R Goggs, MT Harper, RJ Pope, JS Savage, CM Williams, SJ Mundell, ... Journal of Biological Chemistry 288 (47), 34217-34229, 2013	37	2013
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck … A Kong, J Good, A Kirkham, J Savage, R Mant, L Llewellyn, J Parish, ... BMJ Open 10 (3), e033009, 2020	30	2020
UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. PD Nathan, P Gaunt, K Wheatley, SJ Bowden, J Savage, G Faust, ... Journal of Clinical Oncology 34 (15_suppl), 9542-9542, 2016	30	2016
Identification of roles for the SNARE-associated protein, SNAP29, in mouse platelets CM Williams, JS Savage, MT Harper, SF Moore, I Hers, AW Poole Platelets 27 (4), 286-294, 2016	20	2016
Clinical trial management: a profession in crisis? EJ Mitchell, K Goodman, N Wakefield, C Cochran, S Cockayne, ... Trials 23 (1), 357, 2022	8	2022
Comment on “Platelet-Derived Nucleotides Promote Tumor Cell Transendothelial Migration and Metastasis via P2Y2 Receptor” by Schumacher et al. MT Harper, JS Savage, AW Poole Cancer cell 24 (3), 287, 2013	8	2013
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study … T Menne, D Slade, J Savage, S Johnson, J Irving, P Kearns, R Plummer, ... BMJ open 12 (3), e059872, 2022	6	2022
CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults T Veenith, BA Fisher, D Slade, A Rowe, R Sharpe, DR Thickett, ... BMJ open 11 (11), e050202, 2021	6	2021
Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information SF Williamson, MJ Grayling, AP Mander, NM Noor, JS Savage, C Yap, ... Journal of Clinical Epidemiology 150, 72-79, 2022	5	2022
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units SB Love, F Cafferty, C Snowdon, K Carty, J Savage, P Pallmann, ... Trials 23 (1), 757, 2022	5	2022
Protocol for the Tessa Jowell BRAIN MATRIX Platform Study C Watts, J Savage, A Patel, R Mant, V Wykes, U Pohl, H Bulbeck, J Apps, ... BMJ Open 12 (9), e067123, 2022	5	2022
PL02. 09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC) G Middleton, S Popat, P Fletcher, Y Summers, A Greystoke, D Gilligan, ... Journal of Thoracic Oncology 14 (10), S7, 2019	4	2019
A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind … D Bhaskaran, J Savage, A Patel, F Collinson, R Mant, F Boele, L Brazil, ... BMC cancer 24 (1), 83, 2024	1	2024

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs